Roche Beefs Up PCR-Test Portfolio With TIB Molbiol Acquisition

by Vandana Singh, Benzinga Editor

September 9, 2021 7:09 AM | 1 min read |

Roche Holdings AG RHHBY has agreed to acquire TIB Molbiol Group for an undisclosed amount. The deal is expected to close in Q4 of 2021.
The acquisition will enhance Roche's portfolio of molecular diagnostics solutions with a wide range of assays for infectious diseases, such as identifying SARS-CoV-2 variants.
TIB Molbiol's portfolio of over 45 CE-IVD assays and more than 100 research use assays are already available on Roche's installed base of LightCycler PCR systems and MagNA Pure sample preparation systems.
The two companies have collaborated for more than 20 years to address critical healthcare needs.
Price Action: RHHBY shares closed 1.42% lower at $48.49 on Wednesday.

Posted In: M&A News Health Care General Briefs Diagnostics

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.